ATUM

🚀JUST ANNOUNCED: ATUM Launches the discoCHO™ Discovery Cell Line for Rapid and Robust Transient Production of Biologics with Manufacturing in Mind ATUM's new CHO-K1-based discoCHO cell line enables robust transient therapeutic protein expression displaying critical quality attributes similar to those of the stable CHO-K1 manufacturing cell line, miCHO-GS. This advancement in antibody production allows you to bring drugs to market faster, while mitigating risk. For more information on this exciting expansion of our industry-leading ecosystem, read the full release: https://hubs.li/Q02LpWVb0 #Biologics #AntibodyProduction #CellLineProduction #CHOK1

We have a booth and a poster ready for next week's Singapore IMAPAC conference. Mario Pereira and Claes Gustafsson will represent ATUM. Visit our booth and learn how your biotherapeutics can be produced faster, with higher yield and better quality.

Congratulations to our friends at Invenra for establishing the B-Body bispecific antibody platform. Efficient conventional purification, high solubility, subcutaneous-compatible viscosity, and excellent stability, built entirely on a human IgG-like scaffold. And yields from 6-11g/L (!) thanks to ATUM's Leap-In transposon and miCHO cell line. https://lnkd.in/d22y-wSi

mAb administration through subcutaneous (SC) administration would be patient-friendly and much cheaper, but SC has poor bioavailability and short half-life. In a nice paper by University of Maryland School of Medicine, they use liposomal SC delivery of broadly neutralizing mAbs against HIV made by ATUM. The paper shows a significant increase in bioavailability and much-improved pharmacokinetics. https://lnkd.in/gux-pB_e

Stable cell lines are indispensable in drug discovery, biomanufacturing, and personalized medicine. However, their development is complex and time-intensive, with challenges like clonal variability and genetic stability issues. In my latest Biocompare editorial, I explore critical characteristics, challenges, and recent innovations in stable cell line development, with expert insights from Sartorius, Sino Biological, Inc., CYTENA, and ATUM. Discover how new tools like automated cell picking and AI-driven multi-omics address the challenges and speed up development. Read the full article here: https://lnkd.in/eDqViqDV Many thanks to David Apiyo, Chen Yuning, Adrian Zambrano, PhD, and Claes Gustafsson for their valuable contributions!

In a paper sweet as cherry pie and wild as Friday night, Centre des Sciences du Goût et de l'Alimentation - Center for Taste and Feeding Behaviour uses overexpressing constructs from ATUM to show how umami and sweet taste are detected by the TAS1R1/TAS1R3 and TAS1R2/TAS1R3 receptors, and how the two tastes enhance each other. Opens up new ways to modulate sweetness in food https://lnkd.in/gpqXGtqg

A #vaccine to prevent #dysentery?! A team from Vaxcyte, the University of Maryland School of Medicine, and the Walter Reed Army Institute of Research have used constructs from ATUM to identify and produce a broad spectrum multi-epitope vaccine using cell-free protein synthesis. The vaccine elicits robust antibody responses and offers a high level of protection. Read more about this life-saving development in Nature: https://hubs.li/Q0351LkB0

What factors will drive change and propel innovation over the next ten years? ATUM co-founder Claes Gustafsson provides a longer-term look at the future of #biopharma in Chapter 5 of The Medicine Maker's "The Multifaceted Future of Pharma" series. Check it out now! 👉 https://hubs.li/Q034TGcB0

What's in store for pharma in 2025? 🔮 Our chief prognosticator, Claes Gustafsson, predicts the regulatory approval of the first tri-specific antibody, Check out what he other drug development, pharma, and oncology executives have to say in Part 2 of this PharmaVoice round-up! https://hubs.li/Q034vNV_0

Our very own Jennifer A. Codding-Bui, Ph.D., is speaking at Bruker Biosensors' "Biosensors and Friends Symposium" this Thursday, January 30th! In the Bay Area? Make sure you don't miss her thought-provoking talk on "AI and SPR for mAB-like Molecules." Register today! Date: January 30, 2025Time: 05:00 pm – 09:00 pm Registration: Free but mandatory, places limited: https://hubs.li/Q034k2pk0 #ProteinEngineering #Bioengineering